Yuwen Wang
Papers
2
Total Citations
7
H-Index
2
About
Yuwen Wang is a rising urologic oncology researcher whose work centers on improving risk stratification and treatment outcomes for prostate cancer patients. Wang’s major contributions lie at the intersection of machine learning and precision medicine. In a pivotal 2022 multicenter retrospective study, Wang developed and validated a machine learning model that predicts pathological upgrade from combined transperineal systematic and MRI-targeted prostate biopsy to final pathology. This work, which has garnered 5 citations, addresses a critical clinical gap by enabling more accurate risk assessment before definitive treatment. Wang also leads innovative therapeutic trials, including a 2024 multicenter phase II study evaluating neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and very high-risk localized prostate cancer. This trial, with 2 citations, explores whether potent androgen receptor inhibition before radical prostatectomy can improve surgical outcomes and reduce disease progression—a pressing need given the adverse outcomes associated with surgery in this population. Through these complementary lines of investigation, Wang is advancing both diagnostic precision and neoadjuvant treatment strategies, offering tangible improvements for patients facing aggressive prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2